Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 847 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hyperlipidaemia Clear all

Conditions: Hyperlipidemias, Cardiovascular Diseases
Interventions: Dried blood spot testing and phlebotomy; Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atherosclerotic Cardiovascular Disease, Cardiovascular Diseases, Atherosclerosis, Arterial Inflammation, Vascular Diseases, Vascular Disease, Peripheral, Vascular Calcification, High Cholesterol/Hyperlipidemia, Heart Diseases, Heart Attack, Stroke, Cerebrovascular Accident, Carotid Artery Diseases, Carotid Atherosclerosis, Transient Ischemic Attack
Interventions: 99mTc-tilmanocept SPECT/CT scanning; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dyslipidemia
Interventions: Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 2,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 58 more

Conditions: Hypercholesterolemia, Flushing
Interventions: Apple pectin, Aspirin 325 mg, Placebo; Other · Drug
Lead sponsor: Patrick Moriarty, MD, FACP, FACC; Other
Eligibility: 21 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hyperlipidemias, Overweight and Obesity, Diabetes
Interventions: TeleMOVE!, Culinary Rx; Behavioral
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Severe Hypertriglyceridemia
Interventions: Epanova, Lovaza; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure, Burn Pit Exposure, Forever Chemicals, Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia, Hyperlipidemia (E.G., Hypercholesterolemia)
Interventions: Colesevelam, Placebo; Drug
Lead sponsor: University of Rhode Island; Other
Eligibility: 25 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Louisville, Kentucky • Augusta, Maine

Conditions: High Blood Glucose, High Cholesterol, High Cholesterol/Hyperlipidemia, Blood Sugar; High, Obesity & Overweight, Diabetes Type 2
Interventions: FELLAship; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoporosis, Cardiovascular Diseases
Interventions: Soy bread; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypercholesterolemia, Familial
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions: PC2: Primary Care Connect; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Dyslipidemias, High Cholesterol, Hypercholesterolemia, Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
Interventions: Placebo, Obicetrapib; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 2,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 69
States / cities: Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin 20 mg, AEGR-733 5 mg, AEGR-733 10 mg, Placebo, AEGR-733 5 mg + atorvastatin 20 mg, AEGR-733 10 mg + atorvastatin 20 mg; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 17
States / cities: Huntsville, Alabama • Jacksonville, Florida • Ocala, Florida + 12 more

Conditions: Hypercholesterolemia
Interventions: ETC-1002, Placebo, Statin Therapy; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 40
States / cities: Muscle Shoals, Alabama • Chandler, Arizona • Chino, California + 36 more

Conditions: Hyperlipidemias, Diabetes, Depression, Pediatric Asthma, Hypertension
Interventions: WE CARE SDOH System, Standard Pediatric Care; Other
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: Not listed
Enrollment: 68,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Worcester, Massachusetts

Conditions: Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions: torcetrapib/atorvastatin, simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 51
States / cities: Birmingham, Alabama • Mesa, Arizona • Alhambra, California + 48 more

Conditions: Hyperlipidemia and Mixed Dyslipidemia
Interventions: Evolocumab, Standard of Care; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 3,681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 107
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more

Conditions: Homozygous Familial Hypercholesterolemia
Interventions: Not listed
Lead sponsor: The Rogosin Institute; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Dyslipidemia
Interventions: LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 38
States / cities: Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more

Conditions: Hypercholesterolemia
Interventions: Nudge; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions: ALN-PCSSC, Normal Saline; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more

Conditions: Familial Hypercholesterolemia
Interventions: Cascade Screening; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Combined Hyperlipidemia
Interventions: Pravafen, Pravastatin, Fenofibrate; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 57
States / cities: Phoenix, Arizona • Sierra Vista, Arizona • Long Beach, California + 46 more

Conditions: Obesity, Hypercholesterolemia, Hyperglycemia, Hypertriglyceridemia
Interventions: Mediterranean Lemonade, Green Tea, Flavored Water; Other
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

Dried Blood Spot- Statin Pilot Study

Immunomodulatory Effects of PCSK9 Inhibition

Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia

Alternative Options to Minimize Niacin-Induced Flushing

Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors

An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis

Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

FELLAShip to Better Health

Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease

Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies

AEGR-733 and Atorvastatin 20 mg vs. Monotherapy in Moderate Hypercholesterolemia

Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

Social Needs Screening and Chronic Diseases Study (WE CARE)

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia

The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

Using Nudges to Implement Comparative Effectiveness

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults